Instrument Inactif

Autres langues AroCell AB (publ) Nasdaq Stockholm

Actions

AroCell AB (publ) Interim Report January 1st to March 31st, 2024	03/05
AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05
AroCell - New patent approved on the US market	19/04
Swedish Diagnostics Company AroCell Secures US Patent	18/04
New patent approved on the US market	18/04
AroCell Attends Three Prestigious Events: AACR, EAU Congress and COG Nordics	16/04
AroCell publishes the Annual Report for 2023	15/04
AroCell publishes the Annual Report for 2023	12/04
The nomination committee's proposal for the board of AroCell for the Annual General Meeting 2024	12/03
New Study: UBC Rapid can reduce the number of cystoscopies necessary in bladder cancer patients, enabling cost-effective follow-up	12/03
Two Accepted Abstracts at AACR 2024 Explore Clinical Applications of TK1 Biomarker	11/03
AroCell : Presentation at LabRoots 2024	04/03
AroCell Q4 - Nearing positive operating cash flow	23/02
AroCell AB (publ) Interim Report January 1st to December 31st, 2023	22/02
AroCell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
AroCell AB Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
AroCell Names CFO Goes on Parental Leave, Interim CFO Named	01/02
Ellen Dittberner, AroCell's CFO, will be taking parental leave, and Lars Jakobsson will step in as the interim CFO.	01/02
AroCell AB Announces Chief Financial Officer Changes	01/02
AroCell has obtained regulatory approval for TUBEX TF in Ethiopia	26/01

Aucun résultat pour cette recherche